Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Invivyd, Inc. - Common Stock (NQ: IVVD ) 1.650 +0.030 (+1.85%) Streaming Delayed Price Updated: 4:00 PM EDT, Jun 12, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Invivyd, Inc. - Common Stock < Previous 1 2 3 4 Next > Invivyd to Participate at the Jefferies Global Healthcare Conference June 03, 2024 From Invivyd Via GlobeNewswire Invivyd Announces General Alignment with U.S. FDA on a Repeatable, Expedient Emergency Use Authorization Pathway for the Prevention and Treatment of Symptomatic COVID-19, Based on Compact Clinical Programs to Establish Safety and Immunobridging for Serial May 31, 2024 From Invivyd Via GlobeNewswire Invivyd Announces the Appointment of Timothy Lee as Chief Commercial Officer May 31, 2024 From Invivyd Via GlobeNewswire Invivyd to Present Data at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting and 2024 American Transplant Congress (ATC) May 29, 2024 From Invivyd Via GlobeNewswire Invivyd Elects Two New Independent Members to its Board of Directors May 22, 2024 From Invivyd Via GlobeNewswire Invivyd to Participate at the H.C. Wainwright 2nd Annual BioConnect Investor Conference May 13, 2024 From Invivyd Via GlobeNewswire Invivyd Reports First Quarter 2024 Financial Results and Recent Business Highlights May 09, 2024 From Invivyd Via GlobeNewswire Invivyd to Pursue Rapid Immunobridging Pathway to Potential EUA for Treatment of COVID-19 in Moderately to Severely Immunocompromised People, Based on U.S. FDA Feedback May 07, 2024 From Invivyd Via GlobeNewswire Invivyd to Host Conference Call Discussing First Quarter 2024 Financial Results and Business Highlights May 02, 2024 From Invivyd Via GlobeNewswire Invivyd Announces $20 Million to $25 Million Improvement in Projected 2024 Year-End Cash Position April 30, 2024 From Invivyd Via GlobeNewswire Invivyd Receives Healthcare Common Procedure Coding System (HCPCS) Reimbursement Codes from the U.S. Centers for Medicare & Medicaid Services (CMS) Covering PEMGARDA™ April 15, 2024 From Invivyd Via GlobeNewswire Invivyd Announces CEO Transition April 12, 2024 Jeremy Gowler appointed Interim CEO From Invivyd Via GlobeNewswire Invivyd Provides PEMGARDA™ Launch Update and Announces 2024 Net Product Revenue Guidance in the Range of $150 Million to $200 Million April 04, 2024 From Invivyd Via GlobeNewswire Invivyd Reports Full Year 2023 Financial Results and Recent Business Highlights March 28, 2024 From Invivyd Via GlobeNewswire Invivyd Announces Interim Exploratory Data on VYD222 from Ongoing CANOPY Clinical Trial March 22, 2024 From Invivyd Via GlobeNewswire Invivyd Announces FDA Authorization for Emergency Use of PEMGARDA™ (Formerly VYD222) for Pre-exposure Prophylaxis (PrEP) of COVID-19 March 22, 2024 From Invivyd Via GlobeNewswire Invivyd to Participate at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference February 05, 2024 From Invivyd Via GlobeNewswire Invivyd Submits Request for Emergency Use Authorization (EUA) to U.S. FDA for VYD222 for the Pre-exposure Prevention of COVID-19 in Immunocompromised Adults and Adolescents January 03, 2024 From Invivyd Via GlobeNewswire Invivyd Announces Positive Initial Results from Ongoing CANOPY Phase 3 Pivotal Clinical Trial Investigating VYD222 for the Prevention of COVID-19 December 18, 2023 From Invivyd Via GlobeNewswire Invivyd Reports Third Quarter 2023 Financial Results and Recent Business Highlights November 09, 2023 From Invivyd Via GlobeNewswire Invivyd to Host Conference Call Discussing Third Quarter 2023 Financial Results and Business Highlights November 02, 2023 From Invivyd Via GlobeNewswire Invivyd to Participate in Upcoming Investor Conferences October 31, 2023 From Invivyd Via GlobeNewswire Invivyd Announces Dosing of First Participant in CANOPY Phase 3 Pivotal Clinical Trial Investigating VYD222 for the Prevention of Symptomatic COVID-19 September 11, 2023 Initial primary endpoint data anticipated in late 2023 or early Q1 2024 From Invivyd Via GlobeNewswire Invivyd to Participate in Upcoming Investor Conferences September 06, 2023 From Invivyd Via GlobeNewswire Invivyd Appoints William Duke as Chief Financial Officer September 05, 2023 From Invivyd Via GlobeNewswire Bragar Eagel & Squire is Investigating Certain Officers and Directors of Dentsply, and Invivyd on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm August 16, 2023 From Bragar Eagel & Squire Via GlobeNewswire Invivyd Reports Second Quarter 2023 Financial Results and Business Highlights August 10, 2023 From Invivyd Via GlobeNewswire Invivyd to Host Conference Call Discussing Second Quarter 2023 Financial Results and Business Highlights August 03, 2023 From Invivyd Via GlobeNewswire Invivyd Announces Appointment of Sara Cotter to Board Of Directors July 27, 2023 From Invivyd Via GlobeNewswire INVIVYD INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Invivyd, Inc. – IVVD, ADGI July 21, 2023 From Kahn Swick & Foti, LLC Via Business Wire < Previous 1 2 3 4 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.